Hyperlipidemia Drugs Market Report 2025

The hyperlipidemia drugs market size has grown strongly in recent years. It will grow from $23.36 billion in 2024 to $24.74 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular diseases, increasing awareness of cholesterol management, higher incidence of obesity and diabetes, widespread adoption of sedentary lifestyles, and the expanding geriatric population.

The hyperlipidemia drugs market size is expected to see strong growth in the next few years. It will grow to $30.68 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be attributed to the rising demand for personalized medicine and targeted therapies, the increasing adoption of combination therapies for hyperlipidemia, growing awareness of genetic hyperlipidemia disorders, expanded penetration of digital health and telemedicine, and a stronger focus on preventive healthcare and early diagnosis. Major trends anticipated in the forecast period include the development of non-statin alternatives, advancement of biosimilars, incorporation of genomic data into treatment strategies, integration of digital health records for improved management, and innovations in gene-editing technologies.

The rising prevalence of cardiovascular diseases (CVDs) is expected to drive growth in the hyperlipidemia drugs market. CVDs encompass disorders affecting the heart and blood vessels, such as coronary heart disease, stroke, heart failure, and hypertension. The increase in CVDs is largely linked to poor dietary habits, including high intake of saturated fats, trans fats, added sugars, and sodium, which contribute to obesity, high blood pressure, and elevated cholesterol. Hyperlipidemia drugs are essential in managing these conditions by reducing harmful cholesterol and triglyceride levels, thereby lowering the risk of complications and improving patient outcomes. For example, the American Heart Association reported that in 2022, the age-adjusted death rate from cardiovascular disease in the U.S. rose to 233.3 per 100,000, up 4% from 224.4 per 100,000 in 2021, highlighting the growing disease burden.

Pharmaceutical companies are innovating with combination therapies to improve treatment efficiency and patient adherence. Combination therapies integrate two or more active ingredients into a single regimen to more effectively target multiple aspects of a disease. In June 2024, Daewoong Bio Inc., a South Korea-based pharmaceutical company, launched CRA-TG Soft Capsule, combining rosuvastatin with omega-3 fatty acids. Rosuvastatin lowers LDL cholesterol by reducing hepatic cholesterol production, while omega-3 fatty acids help reduce triglycerides. The product uses a patented multi-layer capsule coating to ensure ingredient stability and tolerability while maintaining a standard capsule size.

In July 2025, Eli Lilly and Company acquired Verve Therapeutics Inc., a U.S.-based biotechnology firm, to advance one-time gene-editing therapies targeting the root causes of hyperlipidemia. This acquisition aims to transform cardiovascular treatment by moving from ongoing medication to potentially long-lasting solutions that significantly reduce cardiovascular risk. Verve Therapeutics specializes in clinical-stage gene-editing therapies designed to address the genetic basis of high cholesterol and cardiovascular disease.

Major players in the hyperlipidemia drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Zydus Lifesciences Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd.

North America was the largest region in the hyperlipidemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hyperlipidemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hyperlipidemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Hyperlipidemia drugs are medications designed to reduce elevated levels of lipids, including cholesterol and triglycerides, in the bloodstream. They function through different mechanisms, such as decreasing cholesterol synthesis, promoting its removal, or limiting fat absorption. These drugs help lower the risk of cardiovascular diseases by managing abnormal lipid levels.

The main classes of hyperlipidemia drugs include statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, combination therapies, and other miscellaneous drugs. Statins, for instance, reduce blood cholesterol by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is essential for cholesterol production in the liver. These medications are administered via oral, parenteral, or other routes and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, clinics, and other healthcare facilities.

The hyperlipidemia drugs market research report is one of a series of new reports that provides hyperlipidemia drugs market statistics, including hyperlipidemia drugs industry global market size, regional shares, competitors with a hyperlipidemia drugs market share, detailed hyperlipidemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hyperlipidemia drugs industry. This hyperlipidemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperlipidemia drugs market consists of sales of niacin, lomitapide, mipomersen, bempedoic acid, probucol, fibrates, and omega-3 fatty acid products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.